It was shown that the presence of CTLA-4 on tumor cells is associated with a poor prognosis in breast cancer patients (HR 2.820, p = 0.007) [38], however, there are no definite results from the ongoing clinical trials of anti-CTLA-4 antibodies in the TNBC subtype. This evidence concerns the gene CTLA4 and neoplasm.